Literature DB >> 26538322

Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity.

Susanne Wegmann1, Eduardo A Maury1, Molly J Kirk1, Lubna Saqran1, Allyson Roe1, Sarah L DeVos1, Samantha Nicholls1, Zhanyun Fan1, Shuko Takeda1, Ozge Cagsal-Getkin1, Christopher M William1, Tara L Spires-Jones2, Rose Pitstick3, George A Carlson3, Amy M Pooler4, Bradley T Hyman5.   

Abstract

In Alzheimer's disease and tauopathies, tau protein aggregates into neurofibrillary tangles that progressively spread to synaptically connected brain regions. A prion-like mechanism has been suggested: misfolded tau propagating through the brain seeds neurotoxic aggregation of soluble tau in recipient neurons. We use transgenic mice and viral tau expression to test the hypotheses that trans-synaptic tau propagation, aggregation, and toxicity rely on the presence of endogenous soluble tau. Surprisingly, mice expressing human P301Ltau in the entorhinal cortex showed equivalent tau propagation and accumulation in recipient neurons even in the absence of endogenous tau. We then tested whether the lack of endogenous tau protects against misfolded tau aggregation and toxicity, a second prion model paradigm for tau, using P301Ltau-overexpressing mice with severe tangle pathology and neurodegeneration. Crossed onto tau-null background, these mice had similar tangle numbers but were protected against neurotoxicity. Therefore, misfolded tau can propagate across neural systems without requisite templated misfolding, but the absence of endogenous tau markedly blunts toxicity. These results show that tau does not strictly classify as a prion protein.
© 2015 The Authors.

Entities:  

Keywords:  Alzheimer's disease; P301L tau; neurodegeneration; neurofibrillary tangles; prion‐like

Mesh:

Substances:

Year:  2015        PMID: 26538322      PMCID: PMC4687785          DOI: 10.15252/embj.201592748

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

1.  Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules.

Authors:  T J Singh; J Z Wang; M Novak; E Kontzekova; I Grundke-Iqbal; K Iqbal
Journal:  FEBS Lett       Date:  1996-06-03       Impact factor: 4.124

2.  Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex.

Authors:  Michael J Yetman; Sveinung Lillehaug; Jan G Bjaalie; Trygve B Leergaard; Joanna L Jankowsky
Journal:  Brain Struct Funct       Date:  2015-04-14       Impact factor: 3.270

3.  Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.

Authors:  Beatriz G Perez-Nievas; Thor D Stein; Hwan-Ching Tai; Oriol Dols-Icardo; Thomas C Scotton; Isabel Barroeta-Espar; Leticia Fernandez-Carballo; Estibaliz Lopez de Munain; Jesus Perez; Marta Marquie; Alberto Serrano-Pozo; Mathew P Frosch; Val Lowe; Joseph E Parisi; Ronald C Petersen; Milos D Ikonomovic; Oscar L López; William Klunk; Bradley T Hyman; Teresa Gómez-Isla
Journal:  Brain       Date:  2013-07-03       Impact factor: 13.501

4.  Tau is essential to beta -amyloid-induced neurotoxicity.

Authors:  Mark Rapoport; Hana N Dawson; Lester I Binder; Michael P Vitek; Adriana Ferreira
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

5.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

6.  Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system.

Authors:  S Brandner; A Raeber; A Sailer; T Blättler; M Fischer; C Weissmann; A Aguzzi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

7.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

8.  Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity.

Authors:  Susanne Wegmann; Eduardo A Maury; Molly J Kirk; Lubna Saqran; Allyson Roe; Sarah L DeVos; Samantha Nicholls; Zhanyun Fan; Shuko Takeda; Ozge Cagsal-Getkin; Christopher M William; Tara L Spires-Jones; Rose Pitstick; George A Carlson; Amy M Pooler; Bradley T Hyman
Journal:  EMBO J       Date:  2015-11-04       Impact factor: 11.598

9.  CaMKII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP.

Authors:  M Mayford; J Wang; E R Kandel; T J O'Dell
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

10.  Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse.

Authors:  Jonathan Gilley; Anjan Seereeram; Kunie Ando; Suzanne Mosely; Simon Andrews; Martin Kerschensteiner; Thomas Misgeld; Jean-Pierre Brion; Brian Anderton; Diane P Hanger; Michael P Coleman
Journal:  Neurobiol Aging       Date:  2011-04-13       Impact factor: 4.673

View more
  51 in total

Review 1.  Neurodegenerative Disease Transmission and Transgenesis in Mice.

Authors:  Brittany N Dugger; Daniel P Perl; George A Carlson
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 2.  Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.

Authors:  Lars M Ittner; Matthias Klugmann; Yazi D Ke
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

3.  Formation, release, and internalization of stable tau oligomers in cells.

Authors:  Susanne Wegmann; Samantha Nicholls; Shuko Takeda; Zhanyun Fan; Bradley T Hyman
Journal:  J Neurochem       Date:  2016-11-10       Impact factor: 5.372

Review 4.  A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  Nat Rev Neurosci       Date:  2016-04       Impact factor: 34.870

5.  Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice.

Authors:  Noah R Johnson; Carlo Condello; Shenheng Guan; Abby Oehler; Julia Becker; Marta Gavidia; George A Carlson; Kurt Giles; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

Review 6.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

7.  Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.

Authors:  Sarah L DeVos; Rebecca L Miller; Kathleen M Schoch; Brandon B Holmes; Carey S Kebodeaux; Amy J Wegener; Guo Chen; Tao Shen; Hien Tran; Brandon Nichols; Tom A Zanardi; Holly B Kordasiewicz; Eric E Swayze; C Frank Bennett; Marc I Diamond; Timothy M Miller
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

8.  DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins.

Authors:  Sarah N Fontaine; Dali Zheng; Jonathan J Sabbagh; Mackenzie D Martin; Dale Chaput; April Darling; Justin H Trotter; Andrew R Stothert; Bryce A Nordhues; April Lussier; Jeremy Baker; Lindsey Shelton; Mahnoor Kahn; Laura J Blair; Stanley M Stevens; Chad A Dickey
Journal:  EMBO J       Date:  2016-06-03       Impact factor: 11.598

9.  The use of mouse models to study cell-to-cell transmission of pathological tau.

Authors:  Sneha Narasimhan; Virginia M Y Lee
Journal:  Methods Cell Biol       Date:  2017-07-14       Impact factor: 1.441

Review 10.  Tau-based therapies in neurodegeneration: opportunities and challenges.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  Nat Rev Drug Discov       Date:  2017-10-06       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.